Effectiveness and Safety of OnabotulinumtoxinA in Adolescent Patients with Chronic Migraine

Chronic migraine (CM) significantly affects underage individuals. The study objectives are (1) to analyze the effectiveness and safety of onabotulinumtoxinA (BTX-A) in adolescents with CM; (2) to review the literature on BTX-A use in the pediatric population. This prospective observational study inc...

Descripción completa

Detalles Bibliográficos
Autores: Gómez-Dabó, Laura, Caronna, Edoardo|||0000-0001-5525-0267, Mas-de-les-Valls, Rut, Gallardo López, Victor José|||0000-0002-3042-2007, Alpuente, Alicia|||0000-0001-5296-9401, Torres-Ferrús, Marta|||0000-0003-2856-4134, Pozo-Rosich, Patricia|||0000-0003-0796-4702
Tipo de recurso: artículo
Fecha de publicación:2024
País:España
Institución:Universitat Autònoma de Barcelona
Repositorio:Dipòsit Digital de Documents de la UAB
Idioma:inglés
OAI Identifier:oai:ddd.uab.cat:319980
Acceso en línea:https://ddd.uab.cat/record/319980
https://dx.doi.org/urn:doi:10.3390/toxins16050221
Access Level:acceso abierto
Palabra clave:Migraine
onabotulinumtoxinA
Adolescents
Teenagers
Children
id ES_85c5f7fcd48100b04e8432eca5cead27
oai_identifier_str oai:ddd.uab.cat:319980
network_acronym_str ES
network_name_str España
repository_id_str
spelling Effectiveness and Safety of OnabotulinumtoxinA in Adolescent Patients with Chronic MigraineGómez-Dabó, LauraCaronna, Edoardo|||0000-0001-5525-0267Mas-de-les-Valls, RutGallardo López, Victor José|||0000-0002-3042-2007Alpuente, Alicia|||0000-0001-5296-9401Torres-Ferrús, Marta|||0000-0003-2856-4134Pozo-Rosich, Patricia|||0000-0003-0796-4702MigraineonabotulinumtoxinAAdolescentsTeenagersChildrenChronic migraine (CM) significantly affects underage individuals. The study objectives are (1) to analyze the effectiveness and safety of onabotulinumtoxinA (BTX-A) in adolescents with CM; (2) to review the literature on BTX-A use in the pediatric population. This prospective observational study included patients under 18 years old with CM treated with BTX-A (PREEMPT protocol) as compassionate use. Demographic, efficacy (monthly headache days-MHD; monthly migraine days-MMD; acute medication days/month-AMDM) and side effect data were collected. A ≥ 50% reduction in MHD was considered as a response. Effectiveness and safety were analyzed at 6 and 12 months. A systematic review of the use of BTX-A in children/adolescents was conducted in July 2023. In total, 20 patients were included (median age 15 years [14.75-17], 70% (14/20) females). The median basal frequencies were 28.8 [20-28] MHD, 18 [10-28] MMD and 10 [7.5-21.2] AMDM. Compared with baseline, at 6 months (n = 20), 11 patients (55%) were responders, with a median reduction in MHD of -20 days/month (p = 0.001). At 12 months (n = 14), eight patients (57.1%) were responders, with a median reduction in MHD of -17.5 days/month (p = 0.002). No adverse effects were reported. The literature search showed similar results. Our data supports the concept that BTX-A is effective, well tolerated, and safe in adolescents with CM resistant to oral preventatives. 22024-01-0120242024-01-01Articlehttp://purl.org/coar/resource_type/c_6501VoRhttp://purl.org/coar/version/c_970fb48d4fbd8a85info:eu-repo/semantics/articleapplication/pdfhttps://ddd.uab.cat/record/319980https://dx.doi.org/urn:doi:10.3390/toxins16050221reponame:Dipòsit Digital de Documents de la UABinstname:Universitat Autònoma de BarcelonaInglésengopen accesshttp://purl.org/coar/access_right/c_abf2Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.https://creativecommons.org/licenses/by/4.0/info:eu-repo/semantics/openAccessoai:ddd.uab.cat:3199802026-06-06T12:50:31Z
dc.title.none.fl_str_mv Effectiveness and Safety of OnabotulinumtoxinA in Adolescent Patients with Chronic Migraine
title Effectiveness and Safety of OnabotulinumtoxinA in Adolescent Patients with Chronic Migraine
spellingShingle Effectiveness and Safety of OnabotulinumtoxinA in Adolescent Patients with Chronic Migraine
Gómez-Dabó, Laura
Migraine
onabotulinumtoxinA
Adolescents
Teenagers
Children
title_short Effectiveness and Safety of OnabotulinumtoxinA in Adolescent Patients with Chronic Migraine
title_full Effectiveness and Safety of OnabotulinumtoxinA in Adolescent Patients with Chronic Migraine
title_fullStr Effectiveness and Safety of OnabotulinumtoxinA in Adolescent Patients with Chronic Migraine
title_full_unstemmed Effectiveness and Safety of OnabotulinumtoxinA in Adolescent Patients with Chronic Migraine
title_sort Effectiveness and Safety of OnabotulinumtoxinA in Adolescent Patients with Chronic Migraine
dc.creator.none.fl_str_mv Gómez-Dabó, Laura
Caronna, Edoardo|||0000-0001-5525-0267
Mas-de-les-Valls, Rut
Gallardo López, Victor José|||0000-0002-3042-2007
Alpuente, Alicia|||0000-0001-5296-9401
Torres-Ferrús, Marta|||0000-0003-2856-4134
Pozo-Rosich, Patricia|||0000-0003-0796-4702
author Gómez-Dabó, Laura
author_facet Gómez-Dabó, Laura
Caronna, Edoardo|||0000-0001-5525-0267
Mas-de-les-Valls, Rut
Gallardo López, Victor José|||0000-0002-3042-2007
Alpuente, Alicia|||0000-0001-5296-9401
Torres-Ferrús, Marta|||0000-0003-2856-4134
Pozo-Rosich, Patricia|||0000-0003-0796-4702
author_role author
author2 Caronna, Edoardo|||0000-0001-5525-0267
Mas-de-les-Valls, Rut
Gallardo López, Victor José|||0000-0002-3042-2007
Alpuente, Alicia|||0000-0001-5296-9401
Torres-Ferrús, Marta|||0000-0003-2856-4134
Pozo-Rosich, Patricia|||0000-0003-0796-4702
author2_role author
author
author
author
author
author
dc.subject.none.fl_str_mv Migraine
onabotulinumtoxinA
Adolescents
Teenagers
Children
topic Migraine
onabotulinumtoxinA
Adolescents
Teenagers
Children
description Chronic migraine (CM) significantly affects underage individuals. The study objectives are (1) to analyze the effectiveness and safety of onabotulinumtoxinA (BTX-A) in adolescents with CM; (2) to review the literature on BTX-A use in the pediatric population. This prospective observational study included patients under 18 years old with CM treated with BTX-A (PREEMPT protocol) as compassionate use. Demographic, efficacy (monthly headache days-MHD; monthly migraine days-MMD; acute medication days/month-AMDM) and side effect data were collected. A ≥ 50% reduction in MHD was considered as a response. Effectiveness and safety were analyzed at 6 and 12 months. A systematic review of the use of BTX-A in children/adolescents was conducted in July 2023. In total, 20 patients were included (median age 15 years [14.75-17], 70% (14/20) females). The median basal frequencies were 28.8 [20-28] MHD, 18 [10-28] MMD and 10 [7.5-21.2] AMDM. Compared with baseline, at 6 months (n = 20), 11 patients (55%) were responders, with a median reduction in MHD of -20 days/month (p = 0.001). At 12 months (n = 14), eight patients (57.1%) were responders, with a median reduction in MHD of -17.5 days/month (p = 0.002). No adverse effects were reported. The literature search showed similar results. Our data supports the concept that BTX-A is effective, well tolerated, and safe in adolescents with CM resistant to oral preventatives.
publishDate 2024
dc.date.none.fl_str_mv 2
2024-01-01
2024
2024-01-01
dc.type.none.fl_str_mv Article
http://purl.org/coar/resource_type/c_6501
VoR
http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.openaire.fl_str_mv info:eu-repo/semantics/article
format article
dc.identifier.none.fl_str_mv https://ddd.uab.cat/record/319980
https://dx.doi.org/urn:doi:10.3390/toxins16050221
url https://ddd.uab.cat/record/319980
https://dx.doi.org/urn:doi:10.3390/toxins16050221
dc.language.none.fl_str_mv Inglés
eng
language_invalid_str_mv Inglés
language eng
dc.rights.none.fl_str_mv open access
http://purl.org/coar/access_right/c_abf2
https://creativecommons.org/licenses/by/4.0/
dc.rights.openaire.fl_str_mv info:eu-repo/semantics/openAccess
rights_invalid_str_mv open access
http://purl.org/coar/access_right/c_abf2
https://creativecommons.org/licenses/by/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.source.none.fl_str_mv reponame:Dipòsit Digital de Documents de la UAB
instname:Universitat Autònoma de Barcelona
instname_str Universitat Autònoma de Barcelona
reponame_str Dipòsit Digital de Documents de la UAB
collection Dipòsit Digital de Documents de la UAB
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869412325107171328
score 15,811543

Similares en LA Referencia